Apexigen, Inc.

Apexigen, Inc. is a clinical-stage biopharmaceutical company focused on oncology therapeutics that completed its de-SPAC merger with Brookline Capital Acquisition Corp. (Nasdaq: BCAC), sponsored by Brookline Capital Markets, and began trading on Nasdaq under the ticker APGN in 2022. The SPAC conducted its IPO in 2021, targeting the life sciences and biopharmaceutical sector. The August 2022 Form 8-K filing, accession number 0001193125-22-212570, was submitted to the SEC in the period following the business combination closing, reporting material events associated with the newly public company. Apexigen's pipeline centered on antibody-based cancer immunotherapies at the time of the transaction. Visit SpacDesk and sign up for full data, filings history, and deal analytics on Apexigen and hundreds of other SPAC transactions.